Plasma Fractionation Market Set to Reach USD 72.45 Billion by 2032, Driven by 8.8% CAGR

The global plasma fractionation market was valued at USD 37.31 billion in 2024 and is expected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.8% during the forecast period. In 2024, North America led the market, accounting for a 56.18% share.

The fractionation of human plasma is an essential method to create many life-saving plasma protein therapies, including several coagulation factors, albumin, immunoglobulins, protease inhibitors, and others. The increasing prevalence of several disorders, including primary immunodeficiencies, is driving the demand for plasma fractionation products.

Request A Free Sample Report Pdf: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/plasma-fractionation-market-101614  

List of Key Players Profiled in the Market Report

·        CSL (U.S.)

·        Grifols, S.A (Spain)

·        Takeda Pharmaceutical Company Limited (Japan)

·        Kedrion S.p.A (Italy)

·        Octapharma (Switzerland)

·        Bio Products Laboratory Ltd. (U.K.)

·        Biotest AG (Germany)

·        LFB (France)

Key Market Drivers – Plasma Fractionation Market

 Rising Prevalence of Chronic and Rare Diseases

An increasing number of patients are being diagnosed with chronic conditions such as primary immunodeficiency disorders, hemophilia, and autoimmune diseases like CIDP and Guillain-Barré syndrome. These conditions require consistent and long-term treatment using plasma-derived therapies, boosting market demand.

Growing Demand for Plasma-Derived Therapies

Plasma-based products like immunoglobulins, albumin, and coagulation factors are essential in managing life-threatening conditions. Their role in treating immune deficiencies, bleeding disorders, and trauma-related shock contributes to growing demand globally.

Advancements in Plasma Fractionation Technology

Ongoing improvements in fractionation techniques have led to more efficient and high-purity extraction of plasma components. Innovations in automation, process safety, and regulatory compliance have made production more scalable and cost-effective.

Expansion of Plasma Collection Networks

Key market players are investing in expanding their plasma collection infrastructure. Strategic acquisitions, such as Kedrion’s addition of plasma centers in the Czech Republic, have helped secure raw material supply and expand access to underserved regions.

Government and Regulatory Support

Governments and regulatory agencies are supporting plasma fractionation through public awareness campaigns, streamlined approval processes, and funding for research and infrastructure, creating a favorable environment for market growth.

Segments

Increase in Intravenous Immunoglobulin (IVIG) Product Offerings by Key Players Fueled Segment Expansion

By product, the market is classified into albumin, immunoglobulin, coagulation factors, protease inhibitors, and others. The immunoglobulin segment can be sub-segmented into Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG). The coagulation factors segment can be further sub-segmented into factor IX, factor VIII, prothrombin complex concentrates, fibrinogen concentrates, and others. The immunoglobulin segment commanded the plasma fractionation market share. Increasing incidence of autoimmune diseases and growing awareness about the management of such disorders is driving the demand for intravenous immunoglobulin (IVIG). An increase in IVIG product offerings by key players to fuel segment expansion. 

Rising Adoption of Plasma Proteins in Immunology & Neurology Procedures to Foster Segment Growth

In terms of application, the market is categorized into hematology, critical care, pulmonology, immunology & neurology, and others. The immunology & neurology segment is predicted to rise at a higher growth rate over the projected period. The rising incidence of immunological & neurological diseases led to the extensive use of plasma proteins, including coagulation factors and immunoglobulins, in several treatment procedures.

Increasing Demand for Plasma-derived Therapies from Hospitals & Clinics Boosted Segment Growth

On the basis of end-user, the market is segregated into hospitals & clinics, clinical research laboratories, and others. The hospitals & clinics segment generated the highest revenue in the global market owing to the increasing number of people opting for plasma-derived therapies. Increasing demand for plasma-derived therapies from hospitals with improved infrastructure and technology is propelling segment growth.

From the regional ground, the market is classified into North America, Latin America, Europe, the Middle East & Africa, and Asia Pacific.

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

Report Coverage

The report has studied the market in depth and underlined several crucial aspects and leading market participants. It provides important insights into the recent market trends and key industry developments. In addition to the factors mentioned above, the report covers many other factors that have helped the market grow.

Regional Insights

Increasing Need to Fulfill Rising Demand for Plasma-derived Medicinal Products Boosted Market Growth in North America

North America dominated the global market for plasma fractionation as key players are expanding their geographical presence in the region to fulfill the rising demand for plasma-derived medicinal products.

Market growth in Asia Pacific is driven by the rising spending on pharmaceutical products, evolving healthcare research infrastructure in India and China, and the rising prevalence of hemophilia in Asian countries.

Competitive Landscape

Key Companies Emphasize Collaborations and Partnerships to Strengthen Brand Presence

Top market participants emphasize collaborations and partnerships to strengthen brand presence. Baxter, Kedrion S.p.A., and Takeda Pharmaceutical Company Limited are some of the leading companies in the market. They are concentrating on introducing advanced plasma fractionation products to make a mark in the global market. In April 2023, Takeda Pharmaceutical Company Limited obtained FDA approval for the increased use of HYQVIA (immunoglobulin infusion) to treat primary immunodeficiency disorder in children.

Key Industry Development

July 2024 – Kedrion S.p.A. announced that it had established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo in the U.S. market.

March 2024 – argenx announced the approval of VYVGART (efgartigimod alfa) in Japan for the treatment of primary immune thrombocytopenia.